Latest News and Press Releases

Route 92 Medical and Q'Apel Medical have settled their patent litigation.

Route 92 Medical receives Australian Therapeutic Goods Administration approval for its portfolio of neurovascular interventional products.

First-of-its-kind multicenter study demonstrates the utility of the Monopoint system in procedures to treat idiopathic intracranial hypertension.

Route 92 Medical announces EU and MDSAP certification for its neurovascular stroke-intervention-focused product portfolio.

SAN MATEO, Calif., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular...

Route 92 Medical announces $50 million series F extension equity financing to support its commercial expansion.

Route 92 Medical announces the commercial launch of its FreeClimb 88 catheter system.

Route 92 Medical announces FDA 510(k) clearance for its FreeClimb 54 reperfusion system, part of its growing portfolio of neurovascular devices.

Route 92 Medical announces completion of enrollment in the SUMMIT MAX clinical trial studying their .088" HiPoint Reperfusion Catheter.

Route 92 Medical announces the receipt of its 100th patent for its rapidly growing portfolio of neuromuscular intervention products.